

Daniel M. Weiskopf, WSBA No. 44941
McNaul Ebel Nawrot & Helgren PLLC
600 University Street, Suite 2700
Seattle, WA 98101
(206) 467-1816
dweiskopf@mcnaul.com

Hon. Thomas O. Rice

Shannon Rose Selden,
pending *Pro Hac Vice*
Debevoise & Plimpton LLP
66 Hudson Boulevard
New York, NY 10001
(212) 909-6082
srselden@debevoise.com

Megan McGuiggan,
pending *Pro Hac Vice*
Debevoise & Plimpton LLP
801 Pennsylvania Avenue
Washington, DC 20004
(202) 383-8087
mmcguiggan@debevoise.com

Adam Aukland-Peck,
pending *Pro Hac Vice*
Debevoise & Plimpton LLP
66 Hudson Boulevard
New York, NY 10001
(212) 909-6703
aauklandpeck@debevoise.com

Molly Meegan,
pending *Pro Hac Vice*
American College of Obstetricians
and Gynecologists
409 12th Street SW
Washington, DC 20024
(202) 638-5577
mmeegan@acog.org

Jessica Morris,
pending *Pro Hac Vice*
American College of Obstetricians
and Gynecologists
409 12th Street SW
Washington, DC 20024
(202) 638-5577
jmorris@acog.org

Attorneys for Amici Curiae

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF WASHINGTON
AT SPOKANE

STATE OF WASHINGTON, et al.,
Plaintiffs,

v.

UNITED STATES FOOD AND
DRUG ADMINISTRATION, et al.,
Defendants.

No. 1:23-cv-3026-TOR

BRIEF OF AMICI CURIAE
MEDICAL AND PUBLIC
HEALTH SOCIETIES
IN SUPPORT OF PLAINTIFFS'
MOTION
FOR A PRELIMINARY
INJUNCTION

TABLE OF CONTENTS

I.	INTERESTS OF AMICI CURIAE	1
II.	PRELIMINARY STATEMENT	2
A.	Mifepristone Is Safe and Effective.....	4
1.	Mifepristone Has Been Thoroughly Studied and Is Conclusively Safe.	5
2.	Medication Abortion Offers Comparative Benefits Against Other Forms of Abortion.....	11
B.	Restricting Mifepristone Access Without Justification Harms Patients.	13
C.	The REMS at Issue Harms Patients.	17
III.	CONCLUSION	21

TABLE OF AUTHORITIES

Other Authorities

2000 FDA Approval Memo, Compl. Ex. D, ECF No. 1-5	5
2016 FDA Mifeprex Summary Review, Compl. Ex. J, ECF No. 1-11	6, 7
ACOG Practice Bulletin No. 183, <i>Postpartum Hemorrhage</i> (Oct. 2017)	15
ACOG Practice Bulletin No. 200, <i>Early Pregnancy Loss</i> (Nov. 2018, <i>reaff'd</i> 2021)	4
ACOG Practice Bulletin No. 222, <i>Gestational Hypertension and</i> <i>Preeclampsia</i> (June 2020)	15
ACOG Practice Bulletin No. 225, <i>Medication Abortion Up to 70</i> <i>Days of Gestation</i> (Oct. 2020)	4, 6
Alison G. Cahill et al., <i>Obstetric Care Consensus: Placenta</i> <i>Accreta Spectrum</i> , 132 OBSTETRICS & GYNECOLOGY e259 (2018)	15
Alison Norris et al., <i>Abortion Stigma: A Reconceptualization of</i> <i>Constituents, Causes, and Consequences</i> , 21 WOMEN'S HEALTH ISSUES S49 (2011)	18
ANSIRH, <i>Analysis of Medication Abortion Risk and the FDA</i> <i>Report: Mifepristone U.S. Post-Marketing Adverse Events</i> <i>Summary through 12/31/2018</i> , UNIV. OF CAL., S.F., 1 (Apr. 2019)	8
ANSIRH, <i>Analysis of Medication Abortion Risk and the FDA</i> <i>Report: Mifepristone U.S. Post-Marketing Adverse Events</i> <i>Summary through 6/30/2021</i> , UNIV. OF CAL., S.F., 1 (Nov. 2022)	6

1	ANSIRH, <i>Safety of Abortion in the United States</i> , UNIV. OF	
2	CAL., S.F. 1 (Dec. 2014)	9
3	ANSIRH, <i>U.S. Studies on Medication Abortion without In-</i>	
4	<i>Person Clinician Dispensing of Mifepristone</i> , UNIV. OF CAL.,	
5	S.F. (Oct. 2021).....	7
6	Anthony Mazzeo et al., <i>Delivery of Emergency Care in Rural</i>	
7	<i>Settings</i> , ACEP EMERGENCY MEDICINE PRAC. COMM. (July	
8	2017)	12
9	ASGE Standards of Practice Committee, <i>Complications of</i>	
10	<i>Colonoscopy</i> , 74 AM. SOC’Y FOR GASTROINTESTINAL	
11	ENDOSCOPY 745 (2011)	9
12	Christine Dehlendorf & Tracy Weitz, <i>Access to Abortion</i>	
13	<i>Services: A Neglected Health Disparity</i> , 22 J. HEALTH CARE	
14	FOR THE POOR & UNDERSERVED 415 (2011).....	14
15	Ctr. for Medicare & Medicaid Serv., <i>Advancing Rural Maternal</i>	
16	<i>Health Equity</i> (2022)	15
17	Ctr. for Medicare & Medicaid Serv., <i>CMS Rural Health Strategy</i>	
18	(2018).....	15
19	Daniel Grossman et al., <i>Medication abortion with pharmacist</i>	
20	<i>dispensing of mifepristone</i> , 137 OBSTETRICS & GYNECOLOGY	
21	613 (2021).....	20
22	Danielle Calloway et al., <i>Mifepristone Restrictions and Primary</i>	
23	<i>Care: Breaking the Cycle of Stigma Through a Learning</i>	
24	<i>Collaborative Model in the United States</i> , 104	
25	CONTRACEPTION 24 (2021).....	19, 20
26	Development & Approval Process: Drugs, FDA (Aug. 8, 2008).....	5
	Dina Abbas et al., <i>Outpatient Medical Abortion Is Safe and</i>	
	<i>Effective through 70 Days Gestation</i> , 92 CONTRACEPTION	
	197 (2015).....	6

1	Elizabeth G. Raymond & David A. Grimes, <i>The Comparative</i>	
2	<i>Safety of Legal Induced Abortion and Childbirth in the</i>	
3	<i>United States</i> , 119 OBSTETRICS & GYNECOLOGY 215 (2012)	9
4	Elizabeth G. Raymond et al., <i>First-Trimester Medical Abortion</i>	
5	<i>with Mifepristone 200 mg and Misoprostol: A Systematic</i>	
6	<i>Review</i> , 87 CONTRACEPTION 26 (2013)	7
7	Farah H. Morgan & Marc J. Laufgraben, <i>Mifepristone for</i>	
8	<i>Management of Cushing's Syndrome</i> , 33	
9	PHARMACOTHERAPY 319 (2013)	10
10	FDA Ctr. for Drug Eval. & Research, <i>Medical Review,</i>	
11	<i>Application No. 020687Orig1s020</i> (Mar. 29, 2016)	7, 10
12	Greer Donley, <i>Medication Abortion Exceptionalism</i> , 107	
13	CORNELL L. REV. 627 (2022).....	19, 20
14	Jade Shorter et al., <i>Racial Disparities in Mental Health</i>	
15	<i>Outcomes Among Women with Early Pregnancy Loss</i> , 137	
16	OBSTETRICS & GYNECOLOGY 156 (2021).....	17
17	Jenna Jerman et al., <i>Characteristics of U.S. Abortion Patients in</i>	
18	<i>2014 and Changes Since 2008</i> , GUTTMACHER INST. (May	
19	2016)	15
20	Juanita Chinn et al., <i>Health Equity among Black Women in the</i>	
21	<i>United States</i> , 30 J. WOMEN'S HEALTH 212 (2021)	15
22	Katherine Kortsmit et al., <i>Abortion Surveillance – United States,</i>	
23	<i>2019</i> , 70 CDC MORBIDITY & MORTALITY WKLY. REP. 1	
24	(Nov. 26, 2021).....	8
25	Lyndsey S. Benson et al., <i>Early Pregnancy Loss in the</i>	
26	<i>Emergency Department, 2006–2016</i> , 2 J. AM. C. EMERGENCY	
	PHYSICIANS OPEN e12549 (2021)	12, 14
	March of Dimes, <i>Maternity Care Deserts Report</i> (Oct. 2022),	
	https://www.marchofdimes.org/maternity-care-deserts-report	12

1	Mario Tristan et al., <i>Mifepristone for Uterine Fibroids</i> ,	
2	COCHRANE DATABASE SYST. REV. (Aug. 2012).....	10
3	Mifeprex Labeling, Compl. Ex. M, ECF No. 1-14.....	8
4	Mifepristone Patient Agreement Form, Compl. Ex. Q, ECF No.	
5	1-18	18
6	Mike Mitka, <i>Some Men Who Take Viagra Die—Why?</i> , 283	
7	JAMA 590 (Feb. 2, 2000).....	5, 9
8	Na'amah Razon et al., <i>Exploring the Impact of Mifepristone's</i>	
9	<i>Risk Evaluation and Mitigation Strategy (REMS) on the</i>	
10	<i>Integration of Medication Abortion into US Family Medicine</i>	
11	<i>Primary Care Clinics</i> , 109 CONTRACEPTION 19 (2022).....	20
12	Nat'l Acads. of Sci., Eng'g. & Med., <i>The Safety and Quality of</i>	
13	<i>Abortion Care in the United States</i> , NAT'L ACADS. PRESS 45	
14	(2018).....	6
15	R. Morgan Griffin, <i>Making the Decision on NSAIDs</i> , WEBMD	
16	(Oct. 17 2005), https://www.webmd.com/arthritis/features/	
17	making-decision-on-nsaids	5
18	Rachel Jones et al., <i>COVID-19 Abortion Bans and Their</i>	
19	<i>Implications for Public Health</i> , 52 PERSPS. ON SEXUAL AND	
20	REPROD. HEALTH 65 (2020).....	14
21	Rachel Jones et al., <i>Medication Abortion Now Accounts for</i>	
22	<i>More Than Half of All US Abortions</i> , GUTTMACHER INST.	
23	(Dec. 21, 2022)	6
24	Robin R. Wallace et al., <i>Counseling Women with Early</i>	
25	<i>Pregnancy Failure: Utilizing Evidence, Preserving</i>	
26	<i>Preference</i> , 81 PATIENT ED. & COUNSELING 454 (2010)	14
	Roosa Tikkanen et al., <i>Maternal Mortality and Maternity Care</i>	
	<i>in the United States Compared to 10 Other Developed</i>	
	<i>Countries</i> , COMMONWEALTH FUND (Nov. 18, 2020).....	16

1	Rosalyn Schroeder et al., <i>Trends in Abortion Care in the United</i>	
2	<i>States, 2017–2021</i> , ANSIRH, UNIV. OF CAL., S.F. (2022)	12
3	Siobhan Quenby et al., <i>Miscarriage Matters: The</i>	
4	<i>Epidemiological, Physical, Psychological, and Economic</i>	
5	<i>Costs of Early Pregnancy Loss</i> , 397 LANCET 1658 (2021).....	13, 16
6	Suzanne Zane et al., <i>Abortion-Related Mortality in the United</i>	
7	<i>States, 1998–2010</i> , 126 OBSTETRICS & GYNECOLOGY 258	
8	(2015).....	8
9	Ushma D. Upadhyay et al., <i>Incidence of Emergency Department</i>	
10	<i>Visits and Complications after Abortion</i> , 125 OBSTETRICS &	
11	GYNECOLOGY 175 (2015)	7
12	Xiaobin Wang et al., <i>Conception, Early Pregnancy Loss, and</i>	
13	<i>Time to Clinical Pregnancy: A Population-Based</i>	
14	<i>Prospective Study</i> , 79 FERTILITY & STERILITY 577 (2003)	13
15	Y. X. Zhang, <i>Effect of Mifepristone in the Different Treatments</i>	
16	<i>of Endometriosis</i> , CLIN. & EXP. OBSTETRICS & GYNECOLOGY	
17	350 (2016).....	10
18	Yanxia Cao et al., <i>Efficacy of Misoprostol Combined with</i>	
19	<i>Mifepristone on Postpartum Hemorrhage and Its Effects on</i>	
20	<i>Coagulation Function</i> , 13 INT. J. CLIN. EXP. MED. 2234	
21	(2020).....	10

I. INTERESTS OF *AMICI CURIAE*

Amici curiae are leading medical and public health societies representing physicians, clinicians, and public health professionals who serve patients in Washington and nationwide. Among other organizations, they include the American College of Obstetricians and Gynecologists (“ACOG”), the nation’s leading organization of physicians who provide health services unique to people seeking obstetric or gynecologic care; the American Medical Association (“AMA”), the largest professional association of physicians, residents, and medical students in the country; and the Society for Maternal-Fetal Medicine (“SMFM”), the professional society for maternal-fetal medicine subspecialists, who are obstetricians with additional training in high-risk pregnancies.¹

Amici believe that all patients are entitled to prompt, complete, and unbiased healthcare that is medically and scientifically sound. Ensuring access to evidence-based healthcare and promoting policy that improves patient health are central to *amici*’s missions. *Amici* submit this brief to explain that mifepristone is exceedingly safe and effective and that the Risk Evaluation and

¹ Additional *amici* are described in the Motion for Leave.

1 Mitigation Strategy’s (“REMS”) restrictions on mifepristone currently in
2 place, described *infra*, are medically unnecessary.
3

4 Continuing to unnecessarily restrict access to mifepristone will deprive
5 patients of lifesaving care and set healthcare back by decades. Mifepristone
6 has undergone rigorous testing and review and has been approved for use in
7 the United States for over 20 years. Accordingly, *amici* have a strong interest
8 in ensuring that the science surrounding mifepristone’s safety and efficacy is
9 understood and access to this critical medication is not unduly restricted.
10
11

12 II. PRELIMINARY STATEMENT

13 Medication abortion including mifepristone is safe and effective—as
14 evidenced by over two decades of medical studies and vast data collection.
15 The Food & Drug Administration (“FDA”) based its initial approval in 2000
16 on robust evidence that showed mifepristone was extremely safe. The
17 evidence collected and studies performed since then have only confirmed
18 mifepristone’s safety. Serious side effects occur in *less than 1%* of patients,
19 and major adverse events—significant infection, blood loss, or
20 hospitalization—occur in *less than 0.3%* of patients. The risk of death is
21 almost non-existent. Medication abortion also offers advantages over
22
23
24
25
26

1 procedural abortion because it is less invasive and more accessible, particularly
2 to underserved patient populations.
3

4 Mifepristone is also frequently used for the safe and effective
5 management of miscarriage, which can be dangerous and life threatening if
6 left untreated. Recent research has shown that use of mifepristone, in
7 conjunction with misoprostol, improves safety outcomes for patients
8 experiencing pregnancy loss who are treated through medication abortion.
9

10 While some progress has been made to increase mifepristone's
11 availability, the FDA continues to limit its accessibility through the REMS
12 without justification. The REMS includes: (1) provider-certification
13 restrictions, mandating that providers be specially certified to prescribe
14 mifepristone; (2) authorization forms requiring the patient to recognize they
15 are "end[ing]" their pregnancy by taking mifepristone; and (3) regulations
16 requiring special pharmacy certification. REMS programs do not apply by
17 default and are used only where necessary to keep patients safe—
18 circumstances not present here. The REMS at issue is only a barrier to access
19 and does nothing to protect patients given mifepristone's proven safety. The
20 relief sought in the Amended Complaint should be granted.
21
22
23
24
25
26

A. Mifepristone Is Safe and Effective.

The most common method of medication abortion in the United States is a two-drug regimen: mifepristone is taken in conjunction with misoprostol to end an early pregnancy by emptying the contents of the uterus.² Mifepristone followed by misoprostol is used both to induce abortion and to manage miscarriage or early pregnancy loss, which can be life threatening.³

There is overwhelming scientific evidence supporting mifepristone's safety and efficacy. The REMS creates medically unnecessary burdens for providers and patients seeking abortion or miscarriage management, particularly in areas where care is already limited.

² Mifepristone-misoprostol regimens are more effective than misoprostol-only regimens. ACOG Practice Bulletin No. 225, *Medication Abortion Up to 70 Days of Gestation*, at 4 (Oct. 2020).

³ See ACOG Practice Bulletin No. 200, *Early Pregnancy Loss* (Nov. 2018, *reaff'd* 2021).

1 **1. Mifepristone Has Been Thoroughly Studied and Is**
 2 **Conclusively Safe.**

3 Decades of evidence demonstrate that medication abortion is safe and
 4 effective, with exceptionally low rates of major adverse events. Mifepristone’s
 5 safety profile is on par with, or safer than, over-the-counter painkillers like
 6 ibuprofen, which more than 30 million Americans take in any given day.⁴
 7 Viagra—which is widely prescribed and *not* subject to a comparable REMS
 8 program—carries a substantially higher risk of death than mifepristone.⁵

9 The FDA first approved the use of mifepristone over 20 years ago after
 10 determining, based on extensive clinical trials and sound research, that
 11 mifepristone is safe, effective, and that the health benefits outweighed the
 12 known risks.⁶ In the decades since, hundreds of systemic reviews, trials, and
 13

14 ⁴ See R. Morgan Griffin, *Making the Decision on NSAIDs*, WEBMD
 15 (Oct. 17 2005), [https://www.webmd.com/arthritis/features/making-decision-](https://www.webmd.com/arthritis/features/making-decision-on-nsaids)
 16 on-nsaids.

17 ⁵ Mike Mitka, *Some Men Who Take Viagra Die—Why?*, 283 JAMA
 18 590, 590–93 (Feb. 2, 2000).

19 ⁶ See 2000 FDA Approval Memo, Compl. Ex. D, ECF No. 1-5;
 20 Development & Approval Process: Drugs, FDA (Aug. 8, 2008).

1 observational studies have confirmed the safety and effectiveness of
2 mifepristone up to the 10-week gestational period.⁷ As a result, medication
3 abortion is a commonly preferred form of abortion care,⁸ accounting for most
4 abortions in the U.S. as of 2020,⁹ while maintaining an exceptionally low rate
5 of complications.
6

7
8 Studies have repeatedly concluded that even minor complications
9 arising from medication abortion are rare—yet the REMS inexplicably
10 remains in place without compelling medical justification.¹⁰ Major adverse
11

12
13
14 ⁷ See 2016 FDA Mifeprex Summary Review, Compl. Ex. J, ECF No. 1-
15 11, at 6; ACOG Practice Bulletin No. 225, *supra* note 2.
16

17 ⁸ See ANSIRH, *Analysis of Medication Abortion Risk and the FDA*
18 *Report: Mifepristone U.S. Post-Marketing Adverse Events Summary through*
19 *6/30/2021*, UNIV. OF CAL., S.F. 1, 1–3 (Nov. 2022).
20

21 ⁹ See Rachel Jones et al., *Medication Abortion Now Accounts for More*
22 *Than Half of All US Abortions*, GUTTMACHER INST. (Dec. 21, 2022).
23

24 ¹⁰ See Nat'l Acads. of Sci., Eng'g. & Med., *The Safety and Quality of*
25 *Abortion Care in the United States*, NAT'L ACADS. PRESS 45, 58 (2018); Dina
26

events—which include hospitalization and serious infection or bleeding—are “exceedingly rare,” occurring in approximately 0.3% of cases.¹¹ Studies have shown an even smaller number, between 0.014% and 0.07% of patients, experience serious infection.¹² The FDA has made clear that the same

Abbas et al., *Outpatient Medical Abortion Is Safe and Effective through 70 Days Gestation*, 92 CONTRACEPTION 197 (2015).

¹¹ Ushma D. Upadhyay et al., *Incidence of Emergency Department Visits and Complications after Abortion*, 125 OBSTETRICS & GYNECOLOGY 175, 175–83 (2015) (study of over 55,000 abortions found a major complications rate of 0.23% – 0.31% for medication abortion; 0.16% for procedural abortion (i.e., abortion by aspiration)); *see also* Compl. Ex. J, *supra* note 7; FDA Ctr. for Drug Eval. & Research, *Medical Review, Application No. 020687Orig1s020* at 56 (Mar. 29, 2016) (“2016 FDA Medical Review”); ANSIRH, *U.S. Studies on Medication Abortion without In-Person Clinician Dispensing of Mifepristone*, UNIV. OF CAL., S.F. (Oct. 2021); Elizabeth G. Raymond et al., *First-Trimester Medical Abortion with Mifepristone 200 mg and Misoprostol: A Systematic Review*, 87 CONTRACEPTION 26, 30 (2013).

¹² 2016 FDA Medical Review, *supra* note 11, at 53–54.

1 complications can be observed following a miscarriage, procedural abortion,
 2 or medication abortion—i.e., any time a pregnant uterus is emptied—and that
 3 “[n]o causal relationship between the use of MIFEPREX and misoprostol and
 4 [infections, bleeding, or death] has been established.”¹³
 5

6 The risk of death from medication abortion is near zero.¹⁴ A 2019
 7 analysis of FDA data by the University of San Francisco Medical Center over
 8 an 18-year period found only 13 deaths possibly or probably related to
 9 medication abortion, yielding an approximate mortality rate of 0.00035%.¹⁵
 10 Indeed, there is a greater risk of complications or mortality for procedures like
 11 wisdom tooth removals, tonsillectomies, colonoscopies, or from the use of
 12
 13
 14

15 ¹³ Mifeprex Labeling, Compl. Ex. M, ECF No. 1-14 at 2, 5.
 16

17 ¹⁴ See Katherine Kortsmit et al., *Abortion Surveillance – United States,*
 18 *2019*, 70 CDC MORBIDITY & MORTALITY WKLY. REP. 1, 7, 29 tbl.15 (Nov. 26,
 19 2021); Suzanne Zane et al., *Abortion-Related Mortality in the United States,*
 20 *1998–2010*, 126 OBSTETRICS & GYNECOLOGY 258, 261 (2015).
 21

22 ¹⁵ ANSIRH, *Analysis of Medication Abortion Risk and the FDA Report:*
 23 *Mifepristone U.S. Post-Marketing Adverse Events Summary through*
 24 *12/31/2018*, UNIV. OF CAL., S.F., 1, 1–2 (Apr. 2019).
 25
 26

Viagra, than by any abortion method (medication or procedural).¹⁶ Studies have associated Viagra with 4.9 deaths per 100,000 prescriptions,¹⁷ demonstrated that death from colonoscopy occurs in about 0.03% of cases,¹⁸ and found that the “risk of death associated with childbirth [is] approximately 14 times higher” than the risk associated with an abortion.¹⁹ Put simply, medication abortion is among the safest medical interventions in any category, related to pregnancy or not.

Accordingly, mifepristone’s use has only expanded since its initial approval. It is now used for a variety of other health purposes, including to

¹⁶ ANSIRH, *Safety of Abortion in the United States*, UNIV. OF CAL., S.F. 1, 1–2 (Dec. 2014); ASGE Standards of Practice Committee, *Complications of Colonoscopy*, 74 AM. SOC’Y FOR GASTROINTESTINAL ENDOSCOPY 745, 745 (2011).

¹⁷ Mitka, *supra* note 5.

¹⁸ ASGE Standards of Practice Committee, *supra* note 16, at 747.

¹⁹ Elizabeth G. Raymond & David A. Grimes, *The Comparative Safety of Legal Induced Abortion and Childbirth in the United States*, 119 OBSTETRICS & GYNECOLOGY 215, 216 (2012).

1 treat uterine fibroids and endometriosis,²⁰ to reduce the duration of bleeding or
 2 hemorrhaging during certain serious pregnancy complications,²¹ to and treat
 3 patients with Cushing's Syndrome.²²
 4

5 Mifepristone's safety was evident when it was first approved and has
 6 not changed for decades after rigorous and ongoing scientific study, testing,
 7 and monitoring of post-market data.²³ There is no compelling medical basis
 8 to justify continuing its REMS.
 9

10
 11

 ²⁰ See Mario Tristan et al., *Mifepristone for Uterine Fibroids*,
 12 COCHRANE DATABASE SYST. REV. (Aug. 2012); Y. X. Zhang, *Effect of*
 13 *Mifepristone in the Different Treatments of Endometriosis*, CLIN. & EXP.
 14 OBSTETRICS & GYNECOLOGY 350, 350–53 (2016).
 15

16
 17 ²¹ See, e.g., Yanxia Cao et al., *Efficacy of Misoprostol Combined with*
 18 *Mifepristone on Postpartum Hemorrhage and Its Effects on Coagulation*
 19 *Function*, 13 INT. J. CLIN. EXP. MED. 2234, 2234–40 (2020).
 20

21 ²² See Farah H. Morgan & Marc J. Laufgraben, *Mifepristone for*
 22 *Management of Cushing's Syndrome*, 33 PHARMACOTHERAPY 319, 319–29
 23 (2013).
 24

25 ²³ See 2016 FDA Medical Review, *supra* note 11, at 8.
 26

1 **2. Medication Abortion Offers Comparative Benefits Against**
 2 **Other Forms of Abortion.**

3 Procedural abortion (sometimes referred to as a “surgical abortion,”
 4 though it does not involve “surgery” as that term is generally understood) is
 5 not an adequate substitute for medication abortion. While both methods are
 6 not an adequate substitute for medication abortion. While both methods are
 7 exceedingly safe, procedural abortion and medication abortion are not
 8 equivalent in terms of patient care—procedural abortion can be intrusive in a
 9 way that medication abortion is not. In *amici*’s experience, patients choose
 10 medication over procedural abortion for many reasons, including a desire to
 11 avoid physical contact or the distress of having instruments inserted into the
 12 vagina due to prior sexual assault or trauma; a desire to be able to have the
 13 abortion in the company of loved ones; or simply a desire for privacy. Patients
 14 experiencing miscarriage may choose a mifepristone-misoprostol regimen for
 15 the same reasons, rather than an in-clinic procedure.
 16
 17
 18

19 Additionally, medication abortion may be the only option reasonably
 20 accessible to patients given the lack of available reproductive care and
 21 restrictions many states have imposed or seek to impose on procedural
 22 abortion. This is especially true for patients who are from historically
 23 marginalized populations, are low income, or are living in rural areas that are
 24
 25
 26

1 long distances from medical facilities or otherwise lack trained clinicians.²⁴
 2 Even when medical facilities are reasonably accessible to patients, a significant
 3 number that provide abortion care offer only medication abortion.²⁵ For
 4 patients with certain medical conditions, disabilities, or other extenuating
 5 circumstances (such as a lack of access to child care or the inability to take
 6 time off work or travel long distances), medication abortion is the safest and
 7 most accessible option. Unnecessarily restricting access to mifepristone
 8 through the REMS only exacerbates these issues—without reason—for the
 9 most vulnerable populations.
 10
 11
 12
 13
 14

15 ²⁴ See March of Dimes, *Maternity Care Deserts Report* (Oct. 2022),
 16 <https://www.marchofdimes.org/maternity-care-deserts-report>; Lyndsey S.
 17 Benson et al., *Early Pregnancy Loss in the Emergency Department, 2006–*
 18 *2016*, 2 J. AM. C. EMERGENCY PHYSICIANS OPEN e12549 (2021); Anthony
 19 Mazzeo et al., *Delivery of Emergency Care in Rural Settings*, ACEP
 20 EMERGENCY MEDICINE PRAC. COMM. (July 2017).
 21
 22

23 ²⁵ See Rosalyn Schroeder et al., *Trends in Abortion Care in the United*
 24 *States, 2017–2021*, ANSIRH, UNIV. OF CAL., S.F. (2022).
 25
 26

B. Restricting Mifepristone Access without Justification Harms Patients.

Unnecessarily restricting access to mifepristone has profound impacts on patients, providers, and our healthcare system on a macro-level in ways that are both related and unrelated to abortion.

For instance, mifepristone is frequently used in the management of miscarriages. Worldwide, one in six recognized pregnancies ends in miscarriage,²⁶ and when accounting for unrecognized pregnancies (e.g., where the patient is not aware they are pregnant), that number rises to 25%.²⁷ Without proper care and intervention when needed, miscarriage carries risks of

²⁶ Siobhan Quenby et al., *Miscarriage Matters: The Epidemiological, Physical, Psychological, and Economic Costs of Early Pregnancy Loss*, 397 LANCET 1658, 1658–67 (2021).

²⁷ Xiaobin Wang et al., *Conception, Early Pregnancy Loss, and Time to Clinical Pregnancy: A Population-Based Prospective Study*, 79 FERTILITY & STERILITY 577, 577–84 (2003).

1 hemorrhage, sepsis, and death.²⁸ Pregnant people of color are more likely to
 2 experience early pregnancy loss or miscarriage.²⁹ Restricting the use and
 3 availability of mifepristone for miscarriage management deprives patients,
 4 including a disproportionate amount of patients of color, of the ability to
 5 receive prompt, effective, and critical medical care.
 6
 7

8 The same is true for induced medication abortions. Abortion care can
 9 be lifesaving, especially for people suffering from serious health conditions or
 10 complications related to pregnancy. Medication abortion's relative
 11 availability makes it more accessible to patients who otherwise face challenges
 12 accessing medical care, including low-income patients, rural patients, and
 13 patients of color³⁰—the very people who are most likely to experience
 14
 15

16
 17 ²⁸ Robin R. Wallace et al., *Counseling Women with Early Pregnancy*
 18 *Failure: Utilizing Evidence, Preserving Preference*, 81 PATIENT ED. &
 19 COUNSELING 454, 454–61 (2010).
 20

21 ²⁹ See Benson et al., *supra* note 24.

22 ³⁰ See Christine Dehlendorf & Tracy Weitz, *Access to Abortion*
 23 *Services: A Neglected Health Disparity*, 22 J. HEALTH CARE FOR THE POOR &
 24 UNDERSERVED 415, 418 (2011); Rachel Jones et al., *COVID-19 Abortion Bans*
 25
 26

1 maternal morbidity and more likely to die from pregnancy-related
2 complications.³¹
3

4 Even under the best of circumstances, pregnancy and childbirth impose
5 significant physiological changes that can exacerbate underlying preexisting
6 conditions and can severely compromise health, sometimes permanently.³²
7

8 Pregnancy, particularly when coupled with a preexisting condition, can
9

10 *and Their Implications for Public Health*, 52 PERSPS. ON SEXUAL AND REPROD.
11 HEALTH 65, 66–67 (2020); Jenna Jerman et al., *Characteristics of U.S.*
12 *Abortion Patients in 2014 and Changes Since 2008*, GUTTMACHER INST. (May
13 2016); Ctr. for Medicare & Medicaid Serv., *CMS Rural Health Strategy*, at 2
14 (2018).
15

16
17 ³¹ See Ctr. for Medicare & Medicaid Serv., *Advancing Rural Maternal*
18 *Health Equity*, at 1 (2022); Juanita Chinn et al., *Health Equity among Black*
19 *Women in the United States*, 30 J. WOMEN’S HEALTH 212, 215 (2021).
20

21 ³² See, e.g., ACOG Practice Bulletin No. 222, *Gestational Hypertension*
22 *and Preeclampsia* (June 2020); ACOG Practice Bulletin No. 183, *Postpartum*
23 *Hemorrhage* (Oct. 2017); Alison G. Cahill et al., *Obstetric Care Consensus:*
24 *Placenta Accreta Spectrum*, 132 OBSTETRICS & GYNECOLOGY e259 (2018).
25
26

1 quickly evolve into a life-threatening situation necessitating critical care,
2 including abortion. This phenomenon is particularly apparent in the U.S.,
3 which has the highest maternal mortality rate among developed countries, with
4 rates increasing the most for Black and Hispanic patients.³³

5
6 The harms of unnecessarily restricting mifepristone access
7 disproportionately impact these underserved patient populations. For instance,
8 though people of all races and ethnicities take mifepristone for miscarriage
9 management, Black patients are more likely to need such care. Miscarriage is
10 more common among groups impacted by social inequities, such as pregnant
11 people who are Black, poor, or exposed to environmental pollutants.³⁴ Black
12 patients are also at an increased risk of experiencing major depression
13
14
15
16
17
18
19
20

21 ³³ Roosa Tikkanen et al., *Maternal Mortality and Maternity Care in the*
22 *United States Compared to 10 Other Developed Countries*, COMMONWEALTH
23 FUND (Nov. 18, 2020).

24 ³⁴ See generally Quenby et al., *supra* note 26.

1 following a miscarriage,³⁵ the negative outcomes for which are mitigated by
 2 providers who empower patient autonomy by offering management strategies,
 3 like mifepristone, that are safe and effective. Restricting mifepristone imposes
 4 unnecessary burdens on access to essential reproductive healthcare,
 5 particularly for the country's most vulnerable patient populations.
 6
 7

8 **C. The REMS at Issue Harms Patients.**

9 The REMS harms patients by imposing logistical and administrative
 10 hurdles to health care without any compelling reason. First, the Patient
 11 Agreement Form is medically unnecessary and duplicative of informed
 12 consent. Such forms are particularly burdensome when compared to protocols
 13 for alternative, less-preferred forms of miscarriage management—i.e.,
 14 misoprostol-alone management—which have a similar safety profile but do
 15 *not* require patients to sign any form. Patients are, confusingly, required to
 16 jump through this additional, repetitive, and unnecessary administrative hurdle
 17 to receive the same treatment via a more effective regimen (involving
 18
 19
 20
 21

22 ³⁵ See Jade Shorter et al., *Racial Disparities in Mental Health Outcomes*
 23 *Among Women with Early Pregnancy Loss*, 137 OBSTETRICS & GYNECOLOGY
 24 156 (2021).
 25
 26

1 mifepristone). At minimum, any mandatory forms should be amended to be
 2 tailored to the specific medical needs of the patient. The present form requires
 3 patients to attest that they “have decided to take mifepristone and misoprostol
 4 to *end* [their] pregnancy,”³⁶ which is not accurate in all circumstances. During
 5 miscarriage, pregnancy loss is already in process or has already occurred in
 6 many cases. Requiring miscarriage patients to attest to terminating a
 7 pregnancy is confusing, at best, and harmful, at worst, due to the prevalence
 8 of abortion stigma.³⁷ It could also put patients who seek miscarriage care in
 9 jurisdictions hostile to reproductive care and abortion access in legal jeopardy.

13 Second, the clinician “Certified Provider Requirement” does not
 14 meaningfully benefit patients. Clinicians who commonly provide early
 15 pregnancy care, such as emergency medicine specialists, obstetrician-
 16 gynecologists, family physicians, women’s health nurse practitioners, and
 17

19 ³⁶ See Mifepristone Patient Agreement Form, Compl. Ex. Q, ECF No.
 20 1-18 (emphasis added).
 21

22 ³⁷ See generally Alison Norris et al., *Abortion Stigma: A*
 23 *Reconceptualization of Constituents, Causes, and Consequences*, 21
 24 WOMEN’S HEALTH ISSUES S49 (2011).
 25

1 certified nurse midwives are already trained in pregnancy dating, ectopic risk
2 factors, and general care, rendering the additional certification redundant and
3 unnecessary. This requirement does nothing to improve care, creating yet
4 another administrative burden discouraging clinicians from using mifepristone
5 and complicating their ability to do so.³⁸ Clinicians may also be wary of
6 undergoing the mifepristone certification process due to the stigma and
7 potential legal ramifications associated with providing abortions and the
8 violence and harassment they risk as a result,³⁹ even if those clinicians
9 prescribe mifepristone solely for miscarriage management.⁴⁰ It is not
10 surprising that providers have described the REMS as a barrier to integrating
11
12
13
14
15

16
17 ³⁸ See Greer Donley, *Medication Abortion Exceptionalism*, 107
18 CORNELL L. REV. 627, 644 (2022).

19 ³⁹ See *id.*; see also Danielle Calloway et al., *Mifepristone Restrictions*
20 *and Primary Care: Breaking the Cycle of Stigma through a Learning*
21 *Collaborative Model in the United States*, 104 CONTRACEPTION 24, 25
22 (2021).
23

24 ⁴⁰ See Donley, *supra* note 38.
25
26

1 mifepristone in their practice,⁴¹ whether for induced abortion, miscarriage, or
 2 other treatments.
 3

4 Finally, *amici* expect that the “Pharmacy Certification” requirement is
 5 harmful for the same reasons as provider certification requirements.
 6 Pharmacies are already well-equipped to dispense mifepristone without special
 7 certification.⁴² Certification will force retail pharmacies to make business
 8 decisions weighing the value of distributing mifepristone against the risks—
 9 including potential unfounded litigation from anti-abortion groups and
 10 unwanted public attention, protests, or boycotts for that same reason.⁴³ For
 11 example, national pharmacy chain Walgreens has already indicated that it will
 12 not seek certification, and other large retail pharmacies may follow suit (again,
 13
 14
 15

16
 17 ⁴¹ See, e.g., Calloway et al., *supra* note 39; Na’amah Razon et al.,
 18 *Exploring the Impact of Mifepristone’s Risk Evaluation and Mitigation*
 19 *Strategy (REMS) on the Integration of Medication Abortion into US Family*
 20 *Medicine Primary Care Clinics*, 109 CONTRACEPTION 19 (2022).
 21

22 ⁴² Cf. Daniel Grossman et al., *Medication abortion with pharmacist*
 23 *dispensing of mifepristone*, 137 OBSTETRICS & GYNECOLOGY 613 (2021).
 24

25 ⁴³ See Donley, *supra* note 38, at 646.
 26

1 with rural patients feeling the heaviest impact).⁴⁴ Given that the misoprostol-
2 only alternative can be accessed at *any* pharmacy regardless of certification
3 status, this certification requirement actually incentivizes pharmacies to carry
4 the *less preferred* regimen that offers no safety benefit to patients. Pharmacies
5 that do not seek certification (after weighing the considerations above) will be
6 unable to provide their customers the more effective regimen for medication
7 abortion and will be limited in the types of miscarriage management they can
8 offer—ultimately harming patients by restricting the availability of a safe
9 medication.
10
11
12

13 In sum, eliminating the REMS expands access to a safe and effective
14 drug with virtually no other impact. Removing unnecessary barriers to access
15 this safe, effective, and commonly-used drug will only serve to help patients
16 and the providers who care for them in the long term.
17

18 III. CONCLUSION

19
20 For these reasons and those articulated in Plaintiffs' Brief, we strongly
21 urge the Court to grant the relief sought in the Amended Complaint.
22
23
24

25 ⁴⁴ *Cf. id.* at 665.
26

DATED this 24th day of March 2023.

McNAUL EBEL NAWROT & HELGREN PLLC

By: s/Daniel M. Weiskopf
Daniel M. Weiskopf, WSBA No. 44941

600 University Street, Suite 2700
Seattle, WA 98101
(206) 467-1816
dweiskopf@mcnaul.com

Shannon Rose Selden,
pending *Pro Hac Vice*
Debevoise & Plimpton LLP
66 Hudson Boulevard
New York, NY 10001
(212) 909-6082
srselden@debevoise.com

Megan McGuiggan,
pending *Pro Hac Vice*
Debevoise & Plimpton LLP
801 Pennsylvania Avenue
Washington, DC 20004
(202) 383-8087
mmcguiggan@debevoise.com

Adam Aukland-Peck,
pending *Pro Hac Vice*
Debevoise & Plimpton LLP
66 Hudson Boulevard
New York, NY 10001
(212) 909-6703
aauklandpeck@debevoise.com

Molly Meegan,
pending *Pro Hac Vice*
American College of Obstetricians
and Gynecologists
409 12th Street SW
Washington, DC 20024
(202) 638-5577
mmeegan@acog.org

Jessica Morris,
pending *Pro Hac Vice*
American College of Obstetricians
and Gynecologists
409 12th Street SW
Washington, DC 20024
(202) 638-5577
jmorris@acog.org

Attorneys for Amici Curiae

CERTIFICATE OF SERVICE

I hereby certify that on March 24, 2023, I electronically filed the foregoing with the Clerk of the Court using the CM/ECF system, which will send notification of such filing to all counsel of record who receives CM/ECF notification.

DATED this 24th day of March, 2023.

By: s/Daniel M. Weiskopf
Daniel M. Weiskopf, WSBA No. 44941